Eli Lilly walks away from $176.5m damages after judge overturns Teva win
Teva’s patents protecting migraine drug ruled invalid | Lilly’s motion for a new trial denied | ‘The court does not reach this decision nor overturn a jury verdict lightly’ says Judge Alison Burroughs.
Dykema adds senior counsel to IP team
‘A huge shame’: UPC denies access to pleadings and evidence in Sanofi v Amgen
An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.
NanoString to appeal 10x’s UPC injunction ‘immediately’
The spatial biology firm will appeal the Unified Patent Court’s preliminary injunction | NanoString accuses 10x of ‘misusing non-final court rulings…to eliminate competition in the spatial transcriptomics market’.
Roche unit wins Fed Circ clash over blood clot treatment
Long-running legal dispute tackles questions of enablement and ‘undue experimentation’ | Federal Circuit says it is bound by SCOTUS’ findings in Amgen v Sanofi.
10x Genomics 'overjoyed' to win UPC preliminary injunction
Decision marks first announcement by the UPC of an injunction in open court | Ruling in Munich Local Division forecast to have far-reaching consequences for defendant| Comment from 10x vice president of IP and litigation, Randy Wu.
Pfizer must hand over COVID-19 vaccine knowledge
Moderna alleges that rivals’ vaccine infringes patents filed covering a foundational mRNA technology | Big pharma firm must “specifically describe” awareness of Moderna's work in the mRNA vaccine sphere before the end of the month.
US Court of Appeals sides with Apple in Masimo dispute
Court upholds USPTO and the PTAB decisions over blood-oxygen sensor in smartwatches | Ruling finds Masimo patents to be unpatentable and obvious | Only one claim relating to inconsistency to be reversed.
Bausch Ireland fends off challenge to its cancer patent
Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.
